A Study of Treatment ALK(+) Systemic Anaplastic Large Cell Lymphoma With Crizotinib

Inclusion Criteria: * primary ALK(+) systemic anaplastic large cell lymphoma histologically confirmed by biopsy without therapy * ECOG 0-2 * more than 1 measurable lesions with major axis \>1.5cm and minor axis\>1.0cm * estimated survival \>/3months * Age 18-65 years * Women of childbearing age should have a negative pregnancy test; men and women who need to agree to use effective contraception during the period of treatment and the following 1 years * Signature of informed consent Exclusion Criteria: * Age \<\\ 18years * without ALK(+) systemic anaplastic large cell lymphoma histologically confirmed by biopsy * without measurable lesions * being treated by other drugs in other clinical trials * Pregnant or lactating women, who are not willing to take contraceptive measures during the study period, or are not willing to use effective contraceptive measures during the period of treatment and the following 1 years * Hepatic insufficiency: serum total bilirubin, ALT more than 2 times higher than normal * Renal insufficiency: more than 2 times higher than that of normal serum creatinine * Blood screening period: WBC \< 1 \* 109/L \* 109/L; platelet \< 25; Hb \< 60g/L * HIV test positive